CD22 Redirected Autologous T Cells for ALL
Study Details
Study Description
Brief Summary
This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
The study will consist of three sequential phases: 1) a screening phase, 2) a manufacturing and pre- treatment phase, consisting of apheresis (if applicable) and chemotherapy (if applicable), and 3) a treatment phase, consisting of a CART22 transfused cell infusion and follow up evaluations.
After signing informed consent, patients will undergo screening tests and procedures to determine eligibility. Once patient eligibility is confirmed, patients will have cells collected by leukapheresis to obtain peripheral blood mononuclear cells (PBMC) for CART22 manufacturing, unless adequate numbers of cells are available from a prior apheresis. Cells will be transduced with the anti-CD22 TCRζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration. Cryopreserved historical apheresis products collected from the patient prior to study entry are usable for CART22 manufacturing if collected at an appropriately certified apheresis center and the product meets adequate mononuclear cell yields. If a historical apheresis product is not available, an apheresis procedure will be scheduled for cell procurement after study entry.
Unless contraindicated and medically not advisable based on previous chemotherapy, patients will be given conditioning chemotherapy prior to CART22 cell infusion with the intent of lymphodepletion. Additionally, if the patient's white blood cell (WBC) count is ≤ 1,000 /uL, conditioning/lymphodepleting chemotherapy is NOT required. The chemotherapy will be planned so that the last dose is completed 1-4 days BEFORE the planned infusion of CART22 cells. The chemotherapy start date will vary based on the duration of the selected chemotherapy regimen. If the period from chemotherapy to CART22 infusion is delayed 4 or more weeks, the patient will need to be re-treated with lymphodepleting chemotherapy prior to CART22 infusion.
We will enroll 15 evaluable patients for the primary safety endpoint analysis. Primary safety evaluable patients are those who have received any CART22 cells. The first three subjects infused with CART22 will be staggered by 14 days to allow for monitoring of adverse events, including CRS.
Subjects with a manufactured cell dose that is less than the protocol-specified dose will be scored as a manufacturing failure. These subjects will receive their cell infusion, provided that all other manufacturing release criteria are met.
All patients will have blood tests to assess CART22 safety, engraftment and persistence at regular intervals throughout the study (Visit Evaluation Schedule in Appendix 1). Circulating CART22 T cells subsets will be assessed at various times after infusion. CART22 trafficking will be assessed in bone marrow aspirates, and other tissues, if available. Follow up is planned at a minimum of weekly for 4 weeks, monthly for 6 months, then patients will be followed quarterly for the remainder of the year to obtain a medical history, undergo a physical examination, and blood tests. Additional samples collections and assessments between schedule visits after CART22 cell infusion will be performed as clinically indicated.
Following these evaluations, patients will enter a roll-over study for long term follow-up for up to an additional fourteen years to assess for safety assessments per the FDA guidelines.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: CART22 cells Subjects <50kg will receive 0.2-1 x 107 CART22 cells/kg as a split dose over three days as follows: Day 1, 10% fraction: 0.2-1x106 CART22 cells/kg Day 2, 30% fraction: 0.6-3x106 CART22 cells/kg Day 3, 60% fraction: 1.2-6x106 CART22 cells/kg Subjects ≥50kg will receive 1-5x108 CART22 cells as a split dose over three days as follows: Day 1, 10% fraction: 1-5x107 Day 2, 30% fraction: 0.3-1.5x108 Day 3, 60% fraction: 0.6-3x108 |
Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
|
Outcome Measures
Primary Outcome Measures
- Frequency and severity of adverse events, including, but not limited to, cytokine release syndrome (CRS) [From date of dosing ( day 1 ) up to 50 weeks]
grade 3 and higher toxicity rate (toxicity possibly attributed to CART22)
Secondary Outcome Measures
- Evaluate Overall Complete Remission Rate (ORR) [at Day 28]
- Evaluate overall response rate including complete remission (CR) and complete remission with incomplete blood count recovery (CRi) [From the date of dosing until death, last follow up, relapse or start of new anticancer therapy, whichever comes first up to 50 weeks]
- Evaluate duration of remission (DOR) [at 50 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed informed consent form must be obtained prior to any study procedure.
-
Relapsed or refractory B-cell ALL:
-
2nd or greater BM relapse OR
-
Any marrow relapse after allogeneic HSCT and ≥ 6 months from SCT at infusion OR
-
Any marrow relapse after CAR-modified T cell therapy OR
-
Refractory disease defined as having not achieved a CR after > 2 chemotherapy regimens OR
-
Patients with Ph+ ALL are eligible if they are intolerant to or have failed tyrosine kinase inhibitor therapy OR
-
Ineligible for allogeneic SCT because of:
- Comorbid disease ii. Other contraindications to allogeneic SCT conditioning regimen
- Lack of suitable donor iv. Prior SCT v. Declines allogeneic SCT as a therapeutic option after documented discussion, with expected outcomes, about the role of SCT with a BMT physician not part of the study team g. Patients with CNS3 disease will be eligible if CNS disease is responsive to therapy (at infusion, must meet criteria in Section 5.2)
-
Documentation of CD22 tumor expression in bone marrow or peripheral blood by flow cytometry at relapse.
-
Adequate organ function defined as:
-
A serum creatinine based on age/gender as follows:
Maximum Serum Creatinine (mg/dL) Age 1 to < 2 years Male 0.6 Female 0.6 Age 2 to < 6 years Male 0.8 Female 0.8 Age 6 to < 10 years Male 1.0 Female 1.0 Age 10 to < 13 years Male 1.2 Female 1.2 Age 13 to < 16 years Male 1.5 Female 1.4 Age ≥ 16 years Male 1.7 Female 1.4
- Adequate liver function
- ALT < 500 U/L ii. Bilirubin <3x upper limit of normal iii. ALT and/or bilirubin that exceed these ranges is acceptable if, in the opinion of the investigator (or by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver
- Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea, pulse oxygen > 92% on room air; DLCO > 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator d. Left Ventricle Shortening Fraction (LVSF) ≥ 28% or Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA; in cases where quantitative assessment of LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice.
-
Evidence of disease by standard morphologic or by MRD criteria. A clinical marrow showing disease may be performed at enrollment or within 12 weeks of enrollment.
-
Age 1-29 years.
-
Adequate performance status (Lansky or Karnofsky score ≥50)
-
Subjects of reproductive potential must agree to use acceptable birth control methods.
Exclusion Criteria:
-
Active hepatitis B or active hepatitis C.
-
HIV Infection.
-
Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.
-
Concurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary. For additional details regarding the use of steroids and immunosuppressant medication, please see Section 5.6.
-
CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
-
Pregnant or nursing (lactating) women.
-
Receipt of a prior investigational study agent within 4 weeks prior to screening visit. *Note- patients who have received anti-CD19 CART cells (e.g. CART19/CTL019) on an investigational study where cell infusion occurred greater than 4 weeks before the screening visit are NOT excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States | 19104 |
Sponsors and Collaborators
- University of Pennsylvania
- Children's Hospital of Philadelphia
Investigators
- Principal Investigator: Stephan Grupp, MD, PhD, Children's Hospital of Philadelphia
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 15-012219, 823312
- UPCC 15CT055